NxStage Medical downgraded to Market Perform from Outperform at Northland Following a site visit, Northland downgraded NxStage citing lack of training and reimbursement disincentives in prescribing home-hemo using System One.
NxStage Medical shares attractive following pullback, says Piper Jaffray Piper Jaffray believes shares of NxStage Medical are attractive following the 13.5% pullback since last Wednesday's earnings report. Piper attributes to the weakness to concerns over the BAX blood tubing set contract worth $30M annually that expires at the end of the year and potential competition from Outset Medical. Piper sees no reason to "panic" over the contract and does not believe competition is likely in the next few years as Outset has yet to commence a home hemodialysis clinical trial for its Tablo dialysis machine. The firm reiterates an Overweight rating on NxStage with a $24 price target.